AU2004268377B2 - Cancer treatment with epothilones - Google Patents

Cancer treatment with epothilones Download PDF

Info

Publication number
AU2004268377B2
AU2004268377B2 AU2004268377A AU2004268377A AU2004268377B2 AU 2004268377 B2 AU2004268377 B2 AU 2004268377B2 AU 2004268377 A AU2004268377 A AU 2004268377A AU 2004268377 A AU2004268377 A AU 2004268377A AU 2004268377 B2 AU2004268377 B2 AU 2004268377B2
Authority
AU
Australia
Prior art keywords
treatment
tumor
epothilone
dihydroxy
heptadecane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004268377A
Other languages
English (en)
Other versions
AU2004268377A1 (en
Inventor
Clifford Dilea
Sauveur-Michel Maira
Paul M. J. Mcsheehy
Chiaki Tanaka
Markus Wartmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004268377A1 publication Critical patent/AU2004268377A1/en
Application granted granted Critical
Publication of AU2004268377B2 publication Critical patent/AU2004268377B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2004268377A 2003-09-02 2004-09-01 Cancer treatment with epothilones Ceased AU2004268377B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49954803P 2003-09-02 2003-09-02
US60/499,548 2003-09-02
PCT/EP2004/009737 WO2005020989A1 (en) 2003-09-02 2004-09-01 Cancer treatment with epothilones

Publications (2)

Publication Number Publication Date
AU2004268377A1 AU2004268377A1 (en) 2005-03-10
AU2004268377B2 true AU2004268377B2 (en) 2008-06-26

Family

ID=34272839

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004268377A Ceased AU2004268377B2 (en) 2003-09-02 2004-09-01 Cancer treatment with epothilones

Country Status (9)

Country Link
US (2) US20060235059A1 (https=)
EP (1) EP1663214A1 (https=)
JP (1) JP2007504259A (https=)
CN (1) CN1870995A (https=)
AU (1) AU2004268377B2 (https=)
BR (1) BRPI0414043A (https=)
CA (1) CA2537057A1 (https=)
MX (1) MXPA06002393A (https=)
WO (1) WO2005020989A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011084521A2 (en) * 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043320A1 (en) * 1998-02-25 1999-09-02 Novartis Ag Use of epothilones for the treatment of cancer
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US20020169190A1 (en) * 2001-01-25 2002-11-14 Rebanta Bandyopadhyay Methods of administering epothilone analogs for the treatment of cancer
WO2003049734A1 (en) * 2001-12-13 2003-06-19 Novartis Ag Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
WO2003057217A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
EP1503756B1 (en) * 2002-05-01 2009-08-12 Novartis AG Epothilone derivative for the treatment of hepatoma and other cancer diseases
CN101389334A (zh) * 2002-05-20 2009-03-18 高山生物科学股份有限公司 埃坡霉素d的给药方法
BR0313198A (pt) * 2002-08-02 2005-07-12 Novartis Ag Derivados de epotilona
BR0317150A (pt) * 2002-12-09 2005-11-01 Novartis Ag Estabilizadores de microtúbulos em stents para o tratamento de estenose
BRPI0412000A (pt) * 2003-06-27 2006-08-15 Novartis Ag tratamento de cáncer com epotilonas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043320A1 (en) * 1998-02-25 1999-09-02 Novartis Ag Use of epothilones for the treatment of cancer
US20020169190A1 (en) * 2001-01-25 2002-11-14 Rebanta Bandyopadhyay Methods of administering epothilone analogs for the treatment of cancer
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2003049734A1 (en) * 2001-12-13 2003-06-19 Novartis Ag Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
WO2003057217A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANGEWANDTE CHEMIE, August 2003, 42(30), 3515-20 *

Also Published As

Publication number Publication date
US20060235059A1 (en) 2006-10-19
MXPA06002393A (es) 2006-06-20
EP1663214A1 (en) 2006-06-07
JP2007504259A (ja) 2007-03-01
CA2537057A1 (en) 2005-03-10
US20090069394A1 (en) 2009-03-12
CN1870995A (zh) 2006-11-29
BRPI0414043A (pt) 2006-10-24
WO2005020989A1 (en) 2005-03-10
AU2004268377A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
US20090069394A1 (en) Cancer treatment with epothilones
AU755944B2 (en) Use of epothilones for the treatment of cancer
US6302838B1 (en) Cancer treatment with epothilones
EP1052974B1 (en) Pharmaceutical formulation containing epothilone
US6667337B2 (en) Combination therapy for cancer
JP2002504511A5 (https=)
EP2254570B1 (en) Combination comprising paclitaxel for treating ovarian cancer
RU2358730C2 (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
CN111770752A (zh) 瘤内注射制剂
JP2004510734A (ja) ディスタマイシン誘導体を含む抗腫瘍療法
AU2004251444B2 (en) Cancer treatment with epothilones
RU2242229C2 (ru) Применение эпотилонов для лечения рака
AU2003202508B2 (en) Use of epothilones for the treatment of cancer
ES2354193T3 (es) Utilización de epotilonas para el tratamiento del cáncer.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired